ARTL.US Artelo Biosciences Inc

Healthcare Pharmaceuticals USA Stocks
2.07 USD
Close of Nov 13, 2026
1.91 95.04
Market cap
USD 1.13M
P/E
-
P/B
0.23x
ROE
-152.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARTL.US undervalued?

Graham number

The Graham number of Artelo Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Artelo Biosciences Inc fundamental analysis

No fundamental analysis for Artelo Biosciences Inc yet.

Artelo Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxi…

Full company profile